FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3040772495> ?p ?o ?g. }

• W3040772495 endingPage "1872" @default.
• W3040772495 startingPage "1861" @default.
• W3040772495 abstract "A second-generation basal insulin analogue insulin glargine 300 U/mL (Gla-300) has been marketed in France since June 2016. This real-world study was designed to assess persistence with Gla-300 and the prevalence of related hypoglycemia requiring hospitalization as compared to first-generation basal insulins, in patients with type 2 diabetes mellitus (T2DM). A retrospective study was conducted using data in the large French comprehensive national healthcare system claims databases. Patients with T2DM newly treated with insulin in 2016 and 2017 (2-year period) were included. Three basal insulins [Gla-300, glargine 100 U/mL (Gla-100; both branded and biosimilar) and insulin detemir (IDet)] were compared for (1) persistence until treatment discontinuation using adjusted Cox models and (2) hypoglycemia requiring hospitalization over the period of insulin exposure. During the 2-year study period, in France, 181,263 patients initiated basal insulin therapy (in a basal scheme or a more complex insulin scheme), of whom 74% initiated Gla-100, 14.2% initiated IDet and 11.8% initiated Gla-300. Patient characteristics varied according to the insulin regimen in terms of age, gender, social coverage, insulin scheme, and Charlson Comorbidity Index. Overall, 72% of patients were still treated with any basal insulin after 1 year (75% in basal scheme). In all insulin treatment regimens, patients were less likely to discontinue Gla-300 as compared to Gla-100 [adjusted odds ratio (OR) 0.39, 95% confidence interval (CI) 0.37–0.41], with similar results when only the basal scheme was considered (adjusted OR 0.38, 95% CI 0.35–0.40). Persistence with IDet was similar to that with Gla-100. Patients treated with Gla-100 had higher crude hospitalization rates for hypoglycemia than those receiving Gla-300 (1.4 for 100 patients-years; OR 0.67, 95% CI 0.55–0.81); however, this difference was not statistically significant after adjustment for patient characteristics. Emergency Room (ER) visits were less frequent in patients treated with Gla-300 versus Gla-100 with or without adjustment for patient characteristics (p < 0.0001). Real-world persistence for basal insulin therapy in patients with T2DM was significantly better in those on Gla-300 compared with those on Gla-100 and IDet. A trend to a lower frequency of hospitalization for hypoglycemia and ER visits, whatever the cause, was also observed in patients on Gla-300." @default.
• W3040772495 created "2020-07-16" @default.
• W3040772495 creator A5005494512 @default.
• W3040772495 creator A5017513314 @default.
• W3040772495 creator A5025169113 @default.
• W3040772495 creator A5037754769 @default.
• W3040772495 creator A5052950676 @default.
• W3040772495 creator A5057869899 @default.
• W3040772495 date "2020-07-10" @default.
• W3040772495 modified "2023-10-10" @default.
• W3040772495 title "Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes" @default.
• W3040772495 cites W1726580060 @default.
• W3040772495 cites W1808327241 @default.
• W3040772495 cites W1966573008 @default.
• W3040772495 cites W1992480559 @default.
• W3040772495 cites W2014554878 @default.
• W3040772495 cites W2016895882 @default.
• W3040772495 cites W2041650397 @default.
• W3040772495 cites W2100633491 @default.
• W3040772495 cites W2117975938 @default.
• W3040772495 cites W2123946565 @default.
• W3040772495 cites W2139040359 @default.
• W3040772495 cites W2139062201 @default.
• W3040772495 cites W2164733897 @default.
• W3040772495 cites W2171294019 @default.
• W3040772495 cites W2467521096 @default.
• W3040772495 cites W2529901556 @default.
• W3040772495 cites W2742341186 @default.
• W3040772495 cites W2751339385 @default.
• W3040772495 cites W2789047504 @default.
• W3040772495 cites W2807748168 @default.
• W3040772495 cites W2894993577 @default.
• W3040772495 cites W2952421076 @default.
• W3040772495 doi "https://doi.org/10.1007/s13300-020-00874-2" @default.
• W3040772495 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7376764" @default.
• W3040772495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32651837" @default.
• W3040772495 hasPublicationYear "2020" @default.
• W3040772495 type Work @default.
• W3040772495 sameAs 3040772495 @default.
• W3040772495 citedByCount "2" @default.
• W3040772495 countsByYear W30407724952022 @default.
• W3040772495 countsByYear W30407724952023 @default.
• W3040772495 crossrefType "journal-article" @default.
• W3040772495 hasAuthorship W3040772495A5005494512 @default.
• W3040772495 hasAuthorship W3040772495A5017513314 @default.
• W3040772495 hasAuthorship W3040772495A5025169113 @default.
• W3040772495 hasAuthorship W3040772495A5037754769 @default.
• W3040772495 hasAuthorship W3040772495A5052950676 @default.
• W3040772495 hasAuthorship W3040772495A5057869899 @default.
• W3040772495 hasBestOaLocation W30407724951 @default.
• W3040772495 hasConcept C126322002 @default.
• W3040772495 hasConcept C134018914 @default.
• W3040772495 hasConcept C156957248 @default.
• W3040772495 hasConcept C207103383 @default.
• W3040772495 hasConcept C2777180221 @default.
• W3040772495 hasConcept C2778024521 @default.
• W3040772495 hasConcept C2778715236 @default.
• W3040772495 hasConcept C2779306644 @default.
• W3040772495 hasConcept C2779920387 @default.
• W3040772495 hasConcept C2780668416 @default.
• W3040772495 hasConcept C2780677441 @default.
• W3040772495 hasConcept C2781413609 @default.
• W3040772495 hasConcept C2909524832 @default.
• W3040772495 hasConcept C2910068830 @default.
• W3040772495 hasConcept C44249647 @default.
• W3040772495 hasConcept C555293320 @default.
• W3040772495 hasConcept C71924100 @default.
• W3040772495 hasConceptScore W3040772495C126322002 @default.
• W3040772495 hasConceptScore W3040772495C134018914 @default.
• W3040772495 hasConceptScore W3040772495C156957248 @default.
• W3040772495 hasConceptScore W3040772495C207103383 @default.
• W3040772495 hasConceptScore W3040772495C2777180221 @default.
• W3040772495 hasConceptScore W3040772495C2778024521 @default.
• W3040772495 hasConceptScore W3040772495C2778715236 @default.
• W3040772495 hasConceptScore W3040772495C2779306644 @default.
• W3040772495 hasConceptScore W3040772495C2779920387 @default.
• W3040772495 hasConceptScore W3040772495C2780668416 @default.
• W3040772495 hasConceptScore W3040772495C2780677441 @default.
• W3040772495 hasConceptScore W3040772495C2781413609 @default.
• W3040772495 hasConceptScore W3040772495C2909524832 @default.
• W3040772495 hasConceptScore W3040772495C2910068830 @default.
• W3040772495 hasConceptScore W3040772495C44249647 @default.
• W3040772495 hasConceptScore W3040772495C555293320 @default.
• W3040772495 hasConceptScore W3040772495C71924100 @default.
• W3040772495 hasFunder F4320307781 @default.
• W3040772495 hasIssue "8" @default.
• W3040772495 hasLocation W30407724951 @default.
• W3040772495 hasLocation W30407724952 @default.
• W3040772495 hasLocation W30407724953 @default.
• W3040772495 hasLocation W30407724954 @default.
• W3040772495 hasOpenAccess W3040772495 @default.
• W3040772495 hasPrimaryLocation W30407724951 @default.
• W3040772495 hasRelatedWork W1968873653 @default.
• W3040772495 hasRelatedWork W2018460003 @default.
• W3040772495 hasRelatedWork W2030958701 @default.
• W3040772495 hasRelatedWork W2051808761 @default.
• W3040772495 hasRelatedWork W2073392475 @default.
• W3040772495 hasRelatedWork W2091233188 @default.

• next